MedTrace Logo

ALC-919 For The Treatment Of Common Warts

NCT02483455 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2016-03-09

No results posted yet for this study

Summary

This is a single-center, randomized, double blind, vehicle-controlled phase 2 study of subjects 8 years of age and older with Common Warts (Verruca vulgaris) who desire treatment.

Conditions

  • Verruca Vulgaris

Interventions

DRUG

2014-ALC-919-US

A topical solution to be applied twice daily for the treatment of Common Warts

DRUG

Vehicle-Control Topical Solution

A topical solution to be applied twice daily for the treatment of Common Warts

Sponsors & Collaborators

  • Veloce BioPharma LLC

    lead INDUSTRY

Principal Investigators

  • Andrew Pollack, MD · Philadelphia Institute of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02483455 on ClinicalTrials.gov